According to a recent news report from Reuters and experts' opinion therein, a fixed-dose combination drug enabled by hyaluronidase as an active ingredient will be considered a new drug under the revised guidance for the U.S. Medicare Drug Price Negotiation Program implemented by the Inflation Reduction Act (IRA). Therefore, new subcutaneous formulations of innovative drugs with Alteogen's novel recombinant hyaluronidase (ALT-B4) are likely to be excluded from the price negotiations under IRA. Alteogen is confident that ALT-B4 provides both life cycle management and revenue protection tools for drugs of innovative pharmaceutical companies.
ALT-B4 is Alteogen’s proprietary human recombinant human hyaluronidase enzyme developed utilizing the Hybrozyme™ technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are typically administered as an IV infusion. ALT-B4 does this by temporarily hydrolyzing hyaluronan in the extracellular matrix.
About Alteogen Inc.
Alteogen Inc. is a Korean biotechnology company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs) and biobetters and biosimilars, including Eylea®
biosimilar under global phase 3 clinical trial. The company was founded in 2008 and listed in KOSDAQ (196170.KQ).